FDA BPC-157 Compounding Status: 2026 Update

The regulatory path for BPC-157 has shifted several times since the FDA first flagged it for review. For anyone tracking whether this peptide will become available through compounding pharmacies, the timeline matters more than any single headline. We compiled every documented action from the initial Category 2 listing through the July 2026 PCAC advisory vote so you can see where things stand.

Timeline of FDA Actions on BPC-157

Category 2 Listing and the Safety Concern Flag

The FDA maintains a list of bulk drug substances under evaluation for compounding use. Category 2 substances are those the agency considers to raise significant safety or effectiveness concerns. BPC-157 was placed on this list after the FDA determined that insufficient data existed to confirm the peptide's safety when administered to humans. The FDA bulk drug substance page tracks all current assignments.

HHS Announcement (February 2026)

In February 2026, the Department of Health and Human Services issued a statement directing federal agencies to review certain bulk drug substance restrictions. The HHS newsroom published the full statement. This was a policy signal, not a regulatory action. It did not change the compounding status of BPC-157 or any other substance.

Category 2 Removal (April 22, 2026)

On April 22, 2026, the FDA removed BPC-157 from Category 2. This was procedural. Removal did not approve the peptide for human use. It meant the substance was no longer flagged under the specific safety-concern category and could proceed to advisory committee review. The removal appeared in FDA PCAC meeting materials.

PCAC Advisory Vote (July 23-24, 2026): 8-6 for Category 1 (Ulcerative Colitis Indication)

The Pharmacy Compounding Advisory Committee met July 23-24, 2026, and voted 8 to 6 in favor of recommending Category 1 status for a specific indication: ulcerative colitis. Committee members who voted against cited absent Phase II or III data and limited safety information. The proceedings are documented in the FDA PCAC meeting transcripts.

1. Category 2 listed FDA places BPC-157 on the Category 2 bulk drug substance list, citing insufficient human safety data
2. February 2026: HHS announcement Department of Health and Human Services directs review of certain bulk drug substance restrictions
3. April 22, 2026: Category 2 removed FDA removes BPC-157 from Category 2, clearing it for advisory committee evaluation
4. July 23-24, 2026: PCAC advisory vote Committee votes 8-6 to recommend Category 1 status for ulcerative colitis indication only

What the PCAC Vote Means

Advisory Only, Not a Final Rule

The PCAC is an advisory body. Its recommendations inform FDA decision-making but do not bind the agency. The FDA can accept, modify or reject the recommendation. No final rule has been issued as of September 28, 2026.

Tied to Ulcerative Colitis, Not General Use

The 8-6 vote addressed an ulcerative colitis indication specifically. It did not recommend BPC-157 for tissue repair, tendon recovery or any other use discussed in preclinical literature. If the FDA accepts the recommendation, compounding pharmacies could prepare BPC-157 for patients with an ulcerative colitis diagnosis and a prescriber's order.

Rulemaking and Public Comment Period Ahead

Before any compounding pathway is finalized, the FDA must publish a proposed rule in the Federal Register, open a public comment period (typically 60 to 90 days), review comments and issue a final rule. We estimate this could extend into late 2026 or 2027.

What Has Not Changed

BPC-157 Is Still Not FDA-Approved

No FDA approval exists for BPC-157 as a drug product. The PCAC vote relates to compounding eligibility, a separate pathway from new drug approval. Compounded preparations are made by pharmacies under section 503A or 503B and are not FDA-approved products.

Research-Use-Only Labeling Remains

Vendors selling BPC-157 as a research chemical continue to label products "for research use only." This has not changed. The research peptide market operates independently of the compounding pathway.

No OTC Sales Authorized

BPC-157 is not available over the counter. It is not a dietary supplement. DSHEA does not cover synthetic peptides not marketed as supplements before 1994.

What This Means for Buyers

Research Peptides Remain Available Under Existing Rules

Nothing about the PCAC vote changes access to research-use products. Vendors in our brand catalog continue to sell lyophilized BPC-157 vials under existing research-chemical regulations. We have confirmed stock and pricing remain stable across major vendors.

Compounding Pharmacy Access May Expand Late 2026 or 2027

If the FDA finalizes a rule, patients with ulcerative colitis could obtain BPC-157 through a compounding pharmacy with a prescriber's order. This would be a new access pathway, not a replacement for the research peptide market. We will update this page when the FDA publishes a proposed or final rule.